All In Biotech

Drug Trial Radar · NCT06929663

A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 for Injection, an Anti-Trop2/Nectin4 Bispecific Antibody-drug Conjugate, as Monotherapy and in Combination With AK104 or AK112, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

166

Planned (sponsor's estimate)

Start

Jul 2, 2025

Primary completion

Jun 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection, administered as monotherapy and in combination with AK104 or AK112 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • AK146D1 for injectionDrug

    AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate

  • AK112 InjectionDrug

    AK112 is an anti-PD-1/VEGF-A bispecific antibody.

  • AK104 injectionDrug

    AK104 is a recombinant bispecific human monoclonal antibody targeting both anti-programmed cell death 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4(CTLA-4) .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: During the first 3 weeks of treatment.
  2. Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Sydney, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.